Valganciclovir Prophylaxis
Phase 3Small molecule
Valganciclovir Prophylaxis is one of 36 small molecule programs targeting Kidney Transplant. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
121 competitors in Kidney Transplant
#DrugCompanyPhaseTrials
1Ultomiris
AstraZenecaPhase 3
Prevymis
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Felzartamab
BiogenPhase 3
Biological/vaccine
Vertex PharmaceuticalsPhase 3
Envarsus XR
UUniversity of Wisconsin, Madison
Phase 3
Cytogam
JJohns Hopkins University
Phase 3
Valganciclovir Prophylaxis
UUniversity of Guadalajara
Phase 3
Zemplar
AbbViePreclinical
Cysteine Hydrochloride
NovartisPreclinical
Sensipar
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Valganciclovir Prophylaxis. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Guadalajara